Novo Nordisk trims Outlook
Digest more
Novo Nordisk lowered its forecasts due to slowing sales of its obesity drugs amid competition from Eli Lilly and generic ...
Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...
Shares of Novo Nordisk (NYSE:NVO) slipped about 1% on Wednesday morning after the company issued a cautious outlook, even ...
2don MSN
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results